Patient Square Capital

Portfolio Companies 2026 for Patient Square Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Patient Square Capital accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $3.2B. The median disclosed raise is $260M, and the largest is Kriya Therapeutics at $1.2B, ahead of Elevage Medical Technologies ($350M) and Enavate Sciences ($300M).

The names that recur most often on these portfolio cap tables are Patient Square Capital (11 companies), Enavate Sciences (2 companies), Bluebird Ventures (1 company), CAM Capital (1 company), Dexcel Pharma (1 company), Foresite Capital (1 company). By latest disclosed round, the market skews Series C (3), Seed (2), Series A (2), IPO (1).

Best funded Patient Square Capital companies

  1. Kriya Therapeutics — $1.2B (latest: Series C)
  2. Elevage Medical Technologies — $350M
  3. Enavate Sciences — $300M (latest: Seed)
  4. GondolaBio — $300M (latest: Seed)
  5. SOC Telemed — $284M (latest: IPO)
  6. Apollo Therapeutics — $260M (latest: Series C)
  7. Nuclera — $145M (latest: Series C)
  8. Ambros Therapeutics — $125M (latest: Series A)
  9. LXE Hearing — $100M (latest: Growth)
  10. Resolve BioSciences — $100M (latest: Series B)
  11. Graviton — $65M (latest: Series A)

Patient Square Capital — related firms and companies (54)

Patient Square Capital alternatives · All research reports